A Quantitative Measure of Handwriting Dysfluency for Assessing Tardive Dyskinesia

Risk Factors for Tardive Dyskinesia

Second-generation (atypical) antipsychotic agents are being used within their indications as well as widely off-label because of their lower risk of causing extrapyramidal symptoms and tardive dyskinesia (TD). The risk of metabolic disorders has taken over much of clinical practice and the current literature on adverse effects. In this brief article, we discuss a case of TD that developed after...

Risk Factors for Tardive Dyskinesia

Three hundred and fifty three patients who had been on antipsychotics for three months or more were assessed using Simpson Tardive Dyskinesia Rating Scale. 40.2% of these patients, who merited a diagnosis of probable Tardive Dyskinesia (TD) by the Schooler and Kane criteria, were reassessed three months later and 25.5% of the total sample were found to have persistent TD. Age, total antipsychot...

Metoclopramide and tardive dyskinesia.

Metoclopramide (MCP) is a D-2 receptor blocker (Kebabian and Calne 1979), which has been available by prescription in the United States since 1979 for use as an antiemetic in a wide range of situations. One of the common indications for MCP is the &eatment of diabetic gastroparesis (Physicians' Desk Reference 1993). A few recent reports suggest that diabetes mellitus may be a risk factor for ta...

Sulpiride in tardive dyskinesia.

The abnormal involuntary movements in tardive dyskinesia can be reduced by the dopamine antagonist drugs, phenothiazines and butyrophenones, but most cause an increase in Parkinsonian signs. Sulpiride, a benzamide derivative, and selective antagonist of D2 receptors had a significantly beneficial effect on most of 15 patients (p less than 0.01). In 12 patients the improvement was marked. The re...

Clozapine-induced Tardive Dyskinesia